The FDA moved to speed up reviews for multiple psychedelic therapies targeting major depressive disorder, PTSD, and treatment-resistant depression. The agency will use priority review vouchers tied to psilocybin (Compass Pathways), a psilocybin-like program (Usona Institute), and an MDMA-like therapy for PTSD from Transcend Therapeutics. The announcements are part of a Trump administration push to increase access to treatments that have generated both clinical interest and controversy. The FDA identified the voucher recipients’ products, while the companies behind two of the vouchers were confirmed by a source familiar with the matter. Regulators have not indicated pathway details beyond the voucher-based priority mechanism, but the move shortens timelines for review and can influence development sequencing for companies in the category.